Detalhe da pesquisa
1.
Ibrutinib plus Bendamustine and Rituximab in Untreated Mantle-Cell Lymphoma.
N Engl J Med
; 386(26): 2482-2494, 2022 06 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-35657079
2.
SOX11+ Large B-Cell Neoplasms: Cyclin D1-Negative Blastoid/Pleomorphic Mantle Cell Lymphoma or Large B-Cell Lymphoma?
Mod Pathol
; 37(2): 100405, 2024 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-38104893
3.
Therapeutic options for relapsed/refractory mantle cell lymphoma.
Blood
; 139(5): 666-677, 2022 02 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-34679161
4.
Structure of N-terminal domain of NPC1 reveals distinct subdomains for binding and transfer of cholesterol.
Cell
; 137(7): 1213-24, 2009 Jun 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-19563754
5.
Ibrutinib-rituximab followed by R-HCVAD as frontline treatment for young patients (≤65 years) with mantle cell lymphoma (WINDOW-1): a single-arm, phase 2 trial.
Lancet Oncol
; 23(3): 406-415, 2022 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-35074072
6.
Mantle cell lymphoma in 2022-A comprehensive update on molecular pathogenesis, risk stratification, clinical approach, and current and novel treatments.
Am J Hematol
; 97(5): 638-656, 2022 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-35266562
7.
BRUIN MCL-321: phase III study of pirtobrutinib versus investigator choice of BTK inhibitor in BTK inhibitor naive mantle cell lymphoma.
Future Oncol
; 18(36): 3961-3969, 2022 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-36377973
8.
EZH2 expression is associated with inferior overall survival in mantle cell lymphoma.
Mod Pathol
; 34(12): 2183-2191, 2021 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-34376807
9.
Treatment of Mantle-Cell Lymphoma. Reply.
N Engl J Med
; 387(12): 1148, 2022 09 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-36130010
10.
Efficacy of venetoclax in high risk relapsed mantle cell lymphoma (MCL) - outcomes and mutation profile from venetoclax resistant MCL patients.
Am J Hematol
; 95(6): 623-629, 2020 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-32239765
11.
Encouraging activity for R-CHOP in advanced stage nodular lymphocyte-predominant Hodgkin lymphoma.
Blood
; 130(4): 472-477, 2017 07 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-28522441
12.
Four-year follow-up of a single arm, phase II clinical trial of ibrutinib with rituximab (IR) in patients with relapsed/refractory mantle cell lymphoma (MCL).
Br J Haematol
; 182(3): 404-411, 2018 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-29785709
13.
Long-term outcomes and mutation profiling of patients with mantle cell lymphoma (MCL) who discontinued ibrutinib.
Br J Haematol
; 183(4): 578-587, 2018 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-30175400
14.
Frontline Treatment for Older Patients with Mantle Cell Lymphoma.
Oncologist
; 23(11): 1337-1348, 2018 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-29895632
15.
Malignant melanoma with osteosarcomatous differentiation in a lymph node metastasis.
J Cutan Pathol
; 2018 May 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-29781204
16.
Comparative Analysis of Chilblain Lupus Erythematosus and Idiopathic Perniosis: Histopathologic Features and Immunohistochemistry for CD123 and CD30.
Am J Dermatopathol
; 40(4): 265-271, 2018 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-28719438
17.
Targeting Bruton's tyrosine kinase for the treatment of B cell associated malignancies and autoimmune diseases: Preclinical and clinical developments of small molecule inhibitors.
Arch Pharm (Weinheim)
; 351(7): e1700369, 2018 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-29741794
18.
Synergistic activity of BET protein antagonist-based combinations in mantle cell lymphoma cells sensitive or resistant to ibrutinib.
Blood
; 126(13): 1565-74, 2015 Sep 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-26254443
19.
Long-term follow-up of MCL patients treated with single-agent ibrutinib: updated safety and efficacy results.
Blood
; 126(6): 739-45, 2015 Aug 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-26059948
20.
Ibrutinib in combination with rituximab in relapsed or refractory mantle cell lymphoma: a single-centre, open-label, phase 2 trial.
Lancet Oncol
; 17(1): 48-56, 2016 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-26640039